GlaxoSmithKline

Clarivate's 2024 Drugs to Watch report highlights 13 new therapeutics expected to achieve blockbuster status by 2029, targeting conditions like sickle cell disease, RSV, and breast cancer. It also notes the growing chronic disease market in China and the impact of new technologies like CRISPR-Cas9 and AI in drug development.

GSK and Hansoh Pharma announced an exclusive license agreement for HS-20093, a B7-H3 targeted antibody-drug conjugate, showing promising clinical activity in lung cancer. GSK gains worldwide rights (excluding China) for development and commercialization, with Hansoh eligible for up to $1.525 billion in milestones and royalties. HS-20093 is in phase I/II trials in China, with GSK planning phase I trials outside China in 2024.

Seattle Children's launches BrainChild Bio, Inc. to advance CAR T-cell therapies for CNS tumors, focusing on pediatric brain tumors like DIPG. With exclusive license to novel CAR T-cell technology, BrainChild Bio aims to accelerate clinical programs, leveraging Seattle Children’s Therapeutics' expertise and initial funding, to develop safer, effective treatments for children globally.

Seattle Children's Hospital launches BrainChild Bio, a biotech startup focusing on CAR-T cell therapies for pediatric brain tumors, leveraging technology and funding from the hospital. With prior clinical testing and plans for future trials, BrainChild aims for accelerated approval, despite FDA scrutiny over CAR-T therapy's safety risks.

The UK Biobank released nearly half a million whole genome sequences, the largest dataset of its kind, offering insights into disease causes and therapeutic targets. Funded by the UK government, Wellcome, and biopharmaceutical companies, this £200m project enables global researchers to access data for health research, promising transformative results for diagnoses and treatments.

GSK's phase III DREAMM-7 trial shows Blenrep effective as second-line treatment for relapsed/refractory multiple myeloma, improving progression-free survival and showing positive overall survival trend. Blenrep targets B-cell maturation antigen to deliver a cytotoxic agent, with safety profiles consistent with prior data. Detailed findings to be presented soon.

The global sickle cell disease (SCD) treatment market is projected to grow at a CAGR of 19.1% from 2022 to 2030, reaching $4.69 billion. SCD, a common inherited blood disorder, can be detected pre-birth and treated via bone marrow transplants, though donor compatibility is a challenge. Key players like Novartis AG and Pfizer Inc. are expanding their market presence, with recent FDA approvals and acquisitions enhancing treatment options. North America leads the market, with significant growth also expected in Asia Pacific. The development of new drugs and vaccines, alongside public-private partnerships, is driving market expansion.